Novartis receives European Commission approval for self-administration of Xolair across all indications
- The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe[1]
- Xolair? (omalizumab) prefilled syringe (PFS) is the first and only biologic to receive European Commission (EC) approval for self-administration in severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU)
- Novartis is reimagining care in SAA and CSU by providing patients the flexibility to fit their treatment around their lives
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.comEric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | Beyza Oezel Global Head, Respiratory Communications +41 61 696 9503 (direct) +41 79 720 4038 (mobile) beyza.oezel@novartis.com |